Lung cancer remains the deadliest cancer in the United States, yet most individuals eligible for its only proven screening modality, low-dose CT (LDCT), never undergo it. Although LDCT reduces lung cancer mortality by up to 20%, national uptake has stalled at about 16% for more than a decade [1]. The barriers are multifactorial, encompassing stigma, misinformation, and limited engagement at the point of eligibility [1]. But perhaps the question is not only whom we reach, but where we reach them.